Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]H. F. Cheng, J. L. Wang, M. Z. Zhang, Y. Miyazaki, I. Ichikawa, J. A. McKanna and R. C. Harris: Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest, 103(7), 953-61 (1999)

  • [2]P. Harding, D. H. Sigmon, M. E. Alfie, P. L. Huang, M. C. Fishman, W. H. Beierwaltes and O. A. Carretero: Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet. Hypertension, 29(1 Pt 2), 297-302 (1997)

  • [3]H. Francois, C. Facemire, A. Kumar, L. Audoly, B. Koller and T. Coffman: Role of microsomal prostaglandin E synthase 1 in the kidney. J Am Soc Nephrol, 18(5), 1466-75 (2007)

  • [4]T. Miyamoto, N. Ogino, S. Yamamoto and O. Hayaishi: Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem, 251(9), 2629-36 (1976)

  • [5]K. N. Khan, S. K. Paulson, K. M. Verburg, J. B. Lefkowith and T. J. Maziasz: Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int, 61(4), 1210-9 (2002)

  • [6]R. C. Harris: The macula densa: recent developments. J Hypertens, 14(7), 815-22 (1996)

  • [7]C. M. Hao and M. D. Breyer: Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol, 70, 357-77 (2008)

  • [8]M. Z. Zhang, B. Yao, H. F. Cheng, S. W. Wang, T. Inagami and R. C. Harris: Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT(1) and AT(2) receptors. Proc Natl Acad Sci U S A, 103(43), 16045-50 (2006)

  • [9]F. Roig, M. T. Llinas, R. Lopez and F. J. Salazar: Role of cyclooxygenase-2 in the prolonged regulation of renal function. Hypertension, 40(5), 721-8 (2002)

  • [10]T. Yang, I. Singh, H. Pham, D. Sun, A. Smart, J. B. Schnermann and J. P. Briggs: Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol, 274(3 Pt 2), F481-9 (1998)

  • [11]T. Zewde and D. L. Mattson: Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension, 44(4), 424-8 (2004)

  • [12]A. A. Gonzalez, C. Cespedes, S. Villanueva, L. Michea and C. P. Vio: E Prostanoid-1 receptor regulates renal medullary alphaENaC in rats infused with angiotensin II. Biochem Biophys Res Commun, 389(2), 372-7 (2009)

  • [13]S. M. Kim, L. Chen, D. Mizel, Y. G. Huang, J. P. Briggs and J. Schnermann: Low plasma renin and reduced renin secretory responses to acute stimuli in conscious COX-2-deficient mice. Am J Physiol Renal Physiol, 292(1), F415-22 (2007)

  • [14]T. Yang, J. M. Park, L. Arend, Y. Huang, R. Topaloglu, A. Pasumarthy, H. Praetorius, K. Spring, J. P. Briggs and J. Schnermann: Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line. J Biol Chem, 275(48), 37922-9 (2000)

  • [15]F. Hanner, R. Chambrey, S. Bourgeois, E. Meer, I. Mucsi, L. Rosivall, G. E. Shull, J. N. Lorenz, D. Eladari and J. Peti-Peterdi: Increased renal renin content in mice lacking the Na+/H+ exchanger NHE2. Am J Physiol Renal Physiol, 294(4), F937-44 (2008)

  • [16]M. Araujo and W. J. Welch: Tubuloglomerular feedback is decreased in COX-1 knockout mice after chronic angiotensin II infusion. Am J Physiol Renal Physiol, 298(4), F1059-63 (2010)

  • [17]T. Green, J. Rodriguez and L. G. Navar: Augmented cyclooxygenase-2 effects on renal function during varying states of angiotensin II. Am J Physiol Renal Physiol, 299(5), F954-62 (2010)

  • [18]G. Nguyen, F. Delarue, C. Burckle, L. Bouzhir, T. Giller and J. D. Sraer: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest, 109(11), 1417-27 (2002)

  • [19]S. Quadri and H. M. Siragy: Regulation of (pro)renin receptor expression in mIMCD via the GSK-3beta-NFAT5-SIRT-1 signaling pathway. Am J Physiol Renal Physiol, 307(5), F593-600 (2014)

  • [20]C. Li and H. M. Siragy: High glucose induces podocyte injury via enhanced (pro)renin receptor-Wnt-beta-catenin-snail signaling pathway. PLoS One, 9(2), e89233 (2014)

  • [21]J. Huang and H. M. Siragy: Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression. Endocrinology, 150(12), 5557-65 (2009)

  • [22]C. M. Cruciat, B. Ohkawara, S. P. Acebron, E. Karaulanov, C. Reinhard, D. Ingelfinger, M. Boutros and C. Niehrs: Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science, 327(5964), 459-63 (2010)

  • [23]K. Kinouchi, A. Ichihara and H. Itoh: Functional characterization of (pro)renin receptor in association with V-ATPase. Front Biosci (Landmark Ed), 16, 3216-23 (2011)

  • [24]K. J. Binger and D. N. Muller: Autophagy and the (Pro)renin Receptor. Front Endocrinol (Lausanne), 4, 155 (2013)

  • [25]J. Huang and H. M. Siragy: Regulation of (pro)renin receptor expression by glucose-induced mitogen-activated protein kinase, nuclear factor-kappaB, and activator protein-1 signaling pathways. Endocrinology, 151(7), 3317-25 (2010)

  • [26]S. Anderson, H. G. Rennke and B. M. Brenner: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest, 77(6), 1993-2000 (1986)

  • [27]W. Li, M. N. Sullivan, S. Zhang, C. J. Worker, Z. Xiong, R. C. Speth and Y. Feng: Intracerebroventricular infusion of the (Pro)renin receptor antagonist PRO20 attenuates deoxycorticosterone acetate-salt-induced hypertension. Hypertension, 65(2), 352-61 (2015)

  • [28]M. C. Prieto, F. T. Botros, K. Kavanagh and L. G. Navar: Prorenin receptor in distal nephron segments of 2-kidney, 1-clip goldblatt hypertensive rats. Ochsner J, 13(1), 26-32 (2013)

  • [29]J. Huang, K. J. Ledford, W. B. Pitkin, L. Russo, S. M. Najjar and H. M. Siragy: Targeted deletion of murine CEACAM 1 activates PI3K-Akt signaling and contributes to the expression of (Pro)renin receptor via CREB family and NF-kappaB transcription factors. Hypertension, 62(2), 317-23 (2013)

  • [30]S. A. Atlas: The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm, 13(8 Suppl B), 9-20 (2007)

  • [31]S. Higuchi, H. Ohtsu, H. Suzuki, H. Shirai, G. D. Frank and S. Eguchi: Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond), 112(8), 417-28 (2007)

  • [32]E. J. Freeman, M. L. Ruehr and R. V. Dorman: ANG II-induced translocation of cytosolic PLA2 to the nucleus in vascular smooth muscle cells. Am J Physiol, 274(1 Pt 1), C282-8 (1998)

  • [33]J. V. Bonventre: Phospholipase A2 and signal transduction. J Am Soc Nephrol, 3(2), 128-50 (1992)

  • [34]N. O. Dulin, L. D. Alexander, S. Harwalkar, J. R. Falck and J. G. Douglas: Phospholipase A2-mediated activation of mitogen-activated protein kinase by angiotensin II. Proc Natl Acad Sci U S A, 95(14), 8098-102 (1998)

  • [35]R. M. Edwards: Effects of prostaglandins on vasoconstrictor action in isolated renal arterioles. Am J Physiol, 248(6 Pt 2), F779-84 (1985)

  • [36]T. Tomida, Y. Numaguchi, H. Matsui, Y. Toki, T. Ito, K. Okumura and T. Hayakawa: Altered expression of prostacyclin synthase in a subset of the thick ascending limb cells and mesangial cells in 5/6-nephrectomized rats. Hypertens Res, 24(4), 411-9 (2001)

  • [37]R. M. Edwards: Segmental effects of norepinephrine and angiotensin II on isolated renal microvessels. Am J Physiol, 244(5), F526-34 (1983)

  • [38]H. Soejima, Y. Nomura, K. Tsuruta and K. Ikegami: Intrarenal prostaglandins E2 and F2 alpha in experimental renovascular hypertension. Urol Int, 36(3), 158-65 (1981)

  • [39]M. Yoshida, H. Soejima, S. Ueda and K. Ikegami: Role of renal prostaglandin E2 in two-kidney, one-clip renovascular hypertension in rabbits. Nephron, 44(2), 142-9 (1986)

  • [40]H. M. Siragy and R. M. Carey: The subtype 2 angiotensin receptor regulates renal prostaglandin F2 alpha formation in conscious rats. Am J Physiol, 273(3 Pt 2), R1103-7 (1997)

  • [41]M. de Gasparo, K. J. Catt, T. Inagami, J. W. Wright and T. Unger: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev, 52(3), 415-72 (2000)

  • [42]J. Zhuo, I. Moeller, T. Jenkins, S. Y. Chai, A. M. Allen, M. Ohishi and F. A. Mendelsohn: Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens, 16(12 Pt 2), 2027-37 (1998)

  • [43]R. M. Carey and H. M. Siragy: Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev, 24(3), 261-71 (2003)

  • [44]R. M. Carey and S. H. Padia: Role of angiotensin AT(2) receptors in natriuresis: Intrarenal mechanisms and therapeutic potential. Clin Exp Pharmacol Physiol, 40(8), 527-34 (2013)

  • [45]R. A. Santos, A. J. Ferreira, T. Verano-Braga and M. Bader: Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol, 216(2), R1-R17 (2013)

  • [46]J. Yang, C. Chen, H. Ren, Y. Han, D. He, L. Zhou, U. Hopfer, P. A. Jose and C. Zeng: Angiotensin II AT(2) receptor decreases AT(1) receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats. J Hypertens, 30(6), 1176-84 (2012)

  • [47]L. S. Jacobs and J. G. Douglas: Angiotensin II type 2 receptor subtype mediates phospholipase A2-dependent signaling in rabbit proximal tubular epithelial cells. Hypertension, 28(4), 663-8 (1996)

  • [48]H. M. Siragy, M. M. Ibrahim, A. A. Jaffa, R. Mayfield and H. S. Margolius: Rat renal interstitial bradykinin, prostaglandin E2, and cyclic guanosine 3’,5’-monophosphate. Effects of altered sodium intake. Hypertension, 23(6 Pt 2), 1068-70 (1994)

  • [49]H. M. Siragy and R. M. Carey: The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3’, 5’-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest, 97(8), 1978-82 (1996)

  • [50]X. H. Jin, Z. Q. Wang, H. M. Siragy, R. L. Guerrant and R. M. Carey: Regulation of jejunal sodium and water absorption by angiotensin subtype receptors. Am J Physiol, 275(2 Pt 2), R515-23 (1998)

  • [51]W. H. Frishman: Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol, 89(6A), 18D-25D (2002)

  • [52]T. Okumura, I. Hayashi, T. Ikezawa, M. Yamanaka, T. Takata, Y. Fujita, K. Saigenji, S. Yamashina and M. Majima: Cyclooxygenase-2 inhibitors attenuate increased blood pressure in renovascular hypertensive models, but not in deoxycorticosterone-salt hypertension. Hypertens Res, 25(6), 927-38 (2002)

  • [53]J. L. Wang, H. F. Cheng and R. C. Harris: Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension, 34(1), 96-101 (1999)

  • [54]N. Krattinger, F. Alonso, A. Capponi, L. Mazzolai, P. Nicod, P. Meda and J. A. Haefliger: Increased expression of renal cyclooxygenase-2 and neuronal nitric oxide synthase in hypertensive Cx40-deficient mice. J Vasc Res, 46(3), 188-98 (2009)

  • [55]A. A. Gonzalez, T. Green, C. Luffman, C. R. Bourgeois, L. Gabriel Navar and M. C. Prieto: Renal medullary cyclooxygenase-2 and (pro)renin receptor expression during angiotensin II-dependent hypertension. Am J Physiol Renal Physiol, 307(8), F962-70 (2014)

  • [56]A. A. Gonzalez, C. Luffman, C. R. Bourgeois, C. P. Vio and M. C. Prieto: Angiotensin II-independent upregulation of cyclooxygenase-2 by activation of the (Pro)renin receptor in rat renal inner medullary cells. Hypertension, 61(2), 443-9 (2013)

  • [57]M. E. Patterson, J. J. Mullins and K. D. Mitchell: Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension. Am J Physiol Renal Physiol, 294(1), F205-11 (2008)

  • [58]E. A. Jaimes, M. S. Zhou, D. D. Pearse, L. Puzis and L. Raij: Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. Am J Physiol Renal Physiol, 294(2), F385-92 (2008)

  • [59]L. Kopkan, Z. Huskova, Z. Vanourkova, M. Thumova, P. Skaroupkova, J. Maly, H. J. Kramer, P. Dvorak and L. Cervenka: Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats. Vascul Pharmacol, 51(2-3), 175-81 (2009)

  • [60]F. Fan, Y. Muroya and R. J. Roman: Cytochrome P450 eicosanoids in hypertension and renal disease. Curr Opin Nephrol Hypertens, 24(1), 37-46 (2015)

  • [61]R. Bautista, A. Sanchez, J. Hernandez, A. Oyekan and B. Escalante: Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure. Hypertension, 38(3 Pt 2), 669-73 (2001)

  • [62]F. Fan, C. W. Sun, K. G. Maier, J. M. Williams, M. R. Pabbidi, S. P. Didion, J. R. Falck, J. Zhuo and R. J. Roman: 20-Hydroxyeicosatetraenoic acid contributes to the inhibition of K+ channel activity and vasoconstrictor response to angiotensin II in rat renal microvessels. PLoS One, 8(12), e82482 (2013)

  • [63]S. Brouwers, I. Smolders, A. Massie and A. G. Dupont: Angiotensin II type 2 receptor-mediated and nitric oxide-dependent renal vasodilator response to compound 21 unmasked by angiotensin-converting enzyme inhibition in spontaneously hypertensive rats in vivo. Hypertension, 62(5), 920-6 (2013)

  • [64]L. Kumar Bhatt and V. Addepalli: Minocycline with aspirin: an approach to attenuate diabetic nephropathy in rats. Ren Fail, 33(1), 72-8 (2011)

  • [65]L. Vogt, D. de Zeeuw, A. J. Woittiez and G. Navis: Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. Nephrol Dial Transplant, 24(4), 1182-9 (2009)

  • [66]J. Quilley, M. Santos and P. Pedraza: Renal protective effect of chronic inhibition of COX-2 with SC-58236 in streptozotocin-diabetic rats. Am J Physiol Heart Circ Physiol, 300(6), H2316-22 (2011)

  • [67]D. Z. Cherney, J. A. Miller, J. W. Scholey, T. J. Bradley, C. Slorach, J. R. Curtis, M. G. Dekker, R. Nasrallah, R. L. Hebert and E. B. Sochett: The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes, 57(3), 688-95 (2008)

  • [68]R. Komers, J. N. Lindsley, T. T. Oyama, W. E. Schutzer, J. F. Reed, S. L. Mader and S. Anderson: Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest, 107(7), 889-98 (2001)

  • [69]H. Cheng, X. Fan, Y. Guan, G. W. Moeckel, R. Zent and R. C. Harris: Distinct roles for basal and induced COX-2 in podocyte injury. J Am Soc Nephrol, 20(9), 1953-62 (2009)

  • [70]T. Srivastava, E. T. McCarthy, R. Sharma, P. A. Cudmore, M. Sharma, M. L. Johnson and L. F. Bonewald: Prostaglandin E(2) is crucial in the response of podocytes to fluid flow shear stress. J Cell Commun Signal, 4(2), 79-90 (2010)

  • [71]D. Z. Cherney, J. W. Scholey, R. Nasrallah, M. G. Dekker, C. Slorach, T. J. Bradley, R. L. Hebert, E. B. Sochett and J. A. Miller: Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol, 294(6), F1336-41 (2008)

  • [72]Y. Kaneshiro, A. Ichihara, T. Takemitsu, M. Sakoda, F. Suzuki, T. Nakagawa, M. Hayashi and T. Inagami: Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int, 70(4), 641-6 (2006)

  • [73]H. Cheng, X. Fan, G. W. Moeckel and R. C. Harris: Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression. J Am Soc Nephrol, 22(7), 1240-51 (2011)

  • [74]M. Naito, A. Shenoy, I. Aoyama, J. S. Koopmeiners, R. Komers, H. W. Schnaper and K. Bomsztyk: High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin. Am J Nephrol, 30(2), 99-111 (2009)

  • [75]L. C. Matavelli, R. Zatz and H. M. Siragy: A nonpeptide angiotensin II type 2 receptor agonist prevents renal inflammation in early diabetes. J Cardiovasc Pharmacol, 65(4), 371-6 (2015)

  • [76]C. Koulis, B. S. Chow, M. McKelvey, U. M. Steckelings, T. Unger, V. Thallas-Bonke, M. C. Thomas, M. E. Cooper, K. A. Jandeleit-Dahm and T. J. Allen: AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. Hypertension, 65(5), 1073-81 (2015)

  • [77]S. Y. Chang, Y. W. Chen, I. Chenier, M. Tran Sle and S. L. Zhang: Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2. Exp Diabetes Res, 2011, 521076 (2011)

  • [78]I. Antonipillai, J. Nadler, E. J. Vu, S. Bughi, R. Natarajan and R. Horton: A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J Clin Endocrinol Metab, 81(5), 1940-5 (1996)

  • [79]E. M. Abdel-Rahman, P. M. Abadir and H. M. Siragy: Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors. Am J Physiol Regul Integr Comp Physiol, 295(5), R1473-8 (2008)

  • [80]H. M. Siragy, A. A. Jaffa and H. S. Margolius: Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide. Hypertension, 29(3), 757-62 (1997)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2016Article

Interaction of the renin angiotensin and cox systems in the kidney

Syed S. Quadri 1, Silas A. Culver 1, Caixia Li 1, Helmy M. Siragy 1,*
Affiliation
Article Info

1 Division of Endocrinology and Metabolism, University of Virginia Health System, Charlottesville, VA

*Author to whom correspondence should be addressed.

 

Abstract

Cyclooxygenase-2 (COX-2) plays an important role in mediating actions of the renin-angiotensin system (RAS). This review sheds light on the recent developments regarding the complex interactions between components of RAS and COX-2; and their implications on renal function and disease. COX-2 is believed to counter regulate the effects of RAS activation and therefore counter balance the vasoconstriction effect of Ang II. In kidney, under normal conditions, these systems are essential for maintaining a balance between vasodilation and vasoconstriction. However, recent studies suggested a pivotal role for this interplay in pathology. COX-2 increases the renin release and Ang II formation leading to increase in blood pressure. COX-2 is also associated with diabetic nephropathy, where its upregulation in the kidney contributes to glomerular injury and albuminuria. Selective inhibition of COX-2 retards the progression of renal injury. COX-2 also mediates the pathologic effects of the (Pro)renin receptor (PRR) in the kidney. In summary, this review discusses the interaction between the RAS and COX-2 in health and disease.

Keywords

  • Cyclooxygenase-2
  • Angiotensin II
  • Angitensin Type I Receptor
  • Angiotensin Type II Receptor
  • Pro(renin) Receptor.

References